Atopic Dermatitis: Striving for Reliable Biomarkers

Area of Science:

• Immunology
• Dermatology
• Biomarker Discovery

Background:

• Atopic dermatitis (AD) is a complex inflammatory skin condition with diverse clinical presentations and underlying mechanisms.
• Current AD treatment often employs a generalized approach, potentially limiting therapeutic efficacy for many patients.
• There is a significant need for patient stratification through biomarkers to enable precision medicine in AD management.

Purpose of the Study:

• To review prominent candidate biomarkers for atopic dermatitis (AD).
• To discuss the potential utility of these biomarkers in stratifying patients and guiding personalized treatment strategies.
• To highlight the challenges and progress in validating biomarkers for routine clinical use in AD.

Main Methods:

• Literature review of candidate biomarkers for atopic dermatitis (AD).
• Analysis of evidence supporting the correlation of biomarkers with disease severity, comorbidities, and therapeutic response.
• Focus on thymus and activation-regulated chemokine/C-C motif ligand 17 (TARC/CCL17) as a leading candidate biomarker.

Main Results:

• Several candidate biomarkers for AD have been investigated.
• Thymus and activation-regulated chemokine/C-C motif ligand 17 (TARC/CCL17) demonstrates strong evidence as a reliable biomarker for AD.
• TARC/CCL17 is correlated with disease severity in both pediatric and adult AD populations.

Conclusions:

• Validated biomarkers are essential for advancing precision medicine in atopic dermatitis (AD).
• Biomarkers can improve AD diagnosis, severity assessment, and prediction of treatment response.
• TARC/CCL17 is a highly promising biomarker for stratifying AD patients and personalizing treatment.